Literatur zum Artikel Kallert

• Literatur

• 1 Agisiu T, Takahashi K, Yagisawa T. et al. Comparative evaluation of immunoadsorption and double filtration plasmapheresis for removal of anti-A or Anti-B antibody in ABO-incompatible kidney transplantation.. Transpl Proceedings 1992; 24 (02) 1-557.
• 2 Ashworth N, Zochodne D, Hahn A. et al. Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy.. Muscle & Nerve 2000; 23 (02) 2-206.
• 3 ÄZQ/AWMF (Ärztliche Zentralstelle Qualitätssicherung und Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften): Das Leitlinienmanual der AWMT und ÄZQ.. Z ärztl Fortbild Qual sich (Zae FQ). 2001 95. 01 1-84.
• 4 Bahr F, Gerenkamp Th, Leuner Ch, Kuhn H. Langzeitbeobachtung von KHK-Patienten mit familiärer Hypercholesterinämie im LDL-Apherese-Programm.. Z Kardiol 1995; 84 (Suppl. 03) 64.
• 5 Bosch T, Lennertz A, Schmid B. et al. DALI apheresis in hyperlipidemic patients: Biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood.. Artificial Organs 2000; 24 (02) 2-81.
• 6 Bosch T. Current status in extracorporeal immunomodulation: immune disorders.. Artif Organs 1996; 20: 902-905.
• 7 Braun N, Kadar JG, Risler T. Ilerapeutic immunoadsorptionits role in clinical practice.. Transfus Sci 1998; (Suppl. 19) 65-69.
• 8 Brunner R, Randolf A, Widder RA. et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration. A randomized trial.. Retina 2000; 20: 483-491.
• 9 Bundesausschuss der Ärzte und Krankenkassen: Richtlinien über die Einführung neuer Untersuchungs- und Behandlungsmethoden (NUB-Richtlinien).. Deutsches Ärzteblatt 1998; 95: 1930-1931.
• 10 Bundesausschuss der Ärzte und Krankenkassen: Richtlinien zur ambulanten Durchführung der LDL-Elimination.. Deutsches Ärzteblatt 1999; 96: 3000.
• 11 Cole E, Cattran D, Magil A. et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic glomerulonephritis. The Canadian Apheresis Study Group (see comments).. Am J Kidney Dis 1992; 20: 261-269.
• 12 Deutsche Gesellschaft für Kardiologie-, Herz- und Kreislaufforschung: Indikation zur LDL-Eli mination als extrakorporales Hämotherapieverfahren (LDL-Apherese).. Z Kardiol 1997; 86: 478-482.
• 13 Feld SM, Figueroa P, Savin V. et al. Plasmapheresis in the treatment of steroid-resistent focal segmental glomerulosclerosis in native kidneys.. Am J Kidney Dis 1998; 32 (02) 1-230.
• 14 Felix SB, Staudt A, Dörfel WV. et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. Three month results from a randomized study.. J Am Coll Cardiol 2000; 35: 1590-1598.
• 15 Felson DT, Lavalley MP, Baldassarf AR. et al. The Prosorba column for treatment of refractory rheumatoid arthritis.. Arthritis Rheumatism 1999; 42: 2153-2159.
• 16 Franke D, Zimmering M, Wolfish N. et al. Treatment of FSGS with plasma exchange and immunoadsorption.. Pediatr Nephrol 2000; 14: 965-969.
• 17 Furst D, Felson D, Thoren G, Gendreau RM. Immunoadsorption for the treatment of rheumatold arthritis: final results of a randomized trial.. Therapeutic Apheresis 2000; 4 (05) 2-363.
• 18 Gaubitz M, Seidel M, Kummer S. et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.. J Autoimmun 1998; 11: 495-501.
• 19 Gjöratrup P, Grino JM, Niartorell J. et al. Antl-HLA antibody removal in hyperimmunized ESRF patients to allow transplantation.. Transpl Proceedings 1991; 23: 392-395.
• 20 Hidaka T, Suzuki K, Matsuki Y. et al. Filtration leucocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.. Arthritis Rheum 1999; 42 (03) 1-431.
• 21 Hanai H, Watanabe F, Saniabadi AR. et al. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis.. Dig Dis Sci 2002; 47 (10) 2349-2353.
• 22 Hidaka T, Suzuki K, Matsuki Y. et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.. Arthritis Rheum 1999; 42 (03) 431-437.
• 23 Higgins RM, Bevan DJ, Carey BS. et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation.. Lancet 1996; 348: 1208-1211.
• 24 Ilhan O, Arat M, Arslan O. et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.. Transfus Apher Sci 2004; 30 (03) 185-187.
• 25 Kashiwagi N, Sugimura K, Koiwai H. et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis.. Dig Dis Sci 2002; 47 (06) 1334-1341.
• 26 Klingel R, Fassbender C, Fassbender T. et al. Rheopheresis: Pheologic, functional, and structural aspects.. Therapeutic Apheresis 2000; 4 (05) 2-348.
• 27 Koch F, Fischer I, Hattenbach LO. et al. Rheopheresis for age-related macular degeneration.. Kidney Blood Pressure Research 2001; 24: 415-418.
• 28 Kokalj A, Greinix HT, Ciovica M. et al. Effects of extracorporeal photoimmunotherapy on soluble IL-2Ralpha, TNF-RI, and CD8 in patients with steroid-resistant acute graft-versus-host disease.. Clin Immunol 2002; 104 (03) 248-255.
• 29 Kosaka T, Sawada K, Ohnishi K. et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn’s Disease.. Intern Med 1999; 38 (02) 1-102.
• 30 Lewis EJ, Hunsicker LG, Lan SP. et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.. N Engl J Med 1992; 326 (21) 1-1373.
• 31 Maestrangolo F, Pretagostini R, Berloco P. et al. Immunoadsorption with protein A in humoral acute rejection of kidney transplants: multicenter experience.. Transplant Proceedings 1995; 27: 892-895.
• 32 McCann SA, Smith SG. Erythrodermic CTCL: a case study of treatment with extracorporeal photopheresis.. Dermatol Nurs 2000; 12 (02) 103-108 111-2.
• 33 Müller J, Wallukat G, Dandel M. et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.. Circulation 2000; 101: 385-391.
• 34 Müller-Wiefel DE, Tönshoff B, Bulla M. et al. Total recovery of acute renal failure (ARF) after dialysed hemolytic uremic syndrome (HUS) treated with or without membrane plasma separation (MPS).. Pediatr Nephrol 2001; 16: 72.
• 35 Nishimura S, Sekiguchi M, Kanol T. et al. Effects of intensive lipid lowering by LDL-apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterinemia: Japan LDL Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).. Atherosclerosis 1999; 144: 409-417.
• 36 Ogawa H, Matsumoto Y. The efficacy of plasmapheresis or leucocytapheresis for articular and extraarticular manifestations of rheumatoid arthritis.. Therapeutic Apheresis 1997; 1 (04) 1-330.
• 37 Ohta T, Kawaguchi H, Hattori M. et al. Effect of pre- and postoperative plasmapheresis on posttransplant recurrence of focal segmental gi Qmeruloscierosis in children.. Transplantation 2001; 71: 628-633.
• 38 Olbricht CJ, Schleif J, Thiery J. et al. The extracorporeal elimination of LDL cholesterol by apheresis. The indications and methods.. Dtsch Med Wschr 1999; 116: 625-630.
• 39 Persson NH, Bucin D, Ekberg H. et al. Immunoadsorption in acute vascular rejection after renal transplantation.. Transpl Proceedings 1995; 27 (06) 3466.
• 40 Pusey CD, Rees AJ, Evans DJ. et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.. Kidney Int 1991; 40: 757-763.
• 41 Ramlow W, Emmrich J, Ahrenholz P. et al. In vitro and in vivo evaluation of Adacolumn cytapheresis in healthy subjects.. J Clin Apher 2005; 20 (02) 72-80.
• 42 Rech J. Extracorporal therapy in autoimmune diseases and rheumatic processes. arthritis + rheuma 2005; 25 (03) 2-136.
• 43 Reisaeter AV, Leivestad T, Albrechtsen D. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients.. Transplantation 1999; 60: 242-248.
• 44 Richter WO, Jahn P, Jung N. et al. Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience.. Therapeutic Apheresis 2001; 5: 335-339.
• 45 Rock GA, Shumak KH, Buskard NA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.. N Engl J Med 1991; 325-393.
• 46 Ruggenenti P, Galbusera M, Cornejo RP. Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease.. Am J Kidney Dis 1993; 21: 314.
• 47 Sawada K, Ohnishi K, Fukui S. et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowei discase.. J Gastroenterol 1995; 30: 322-329.
• 48 Sawada K, Ohnishi K, Kosaka T. et al. Leukocytapheresis with leukocyte removal filter as a new therapy for ulcerative colitis.. Therapeutic Apheresis 1999; 1: 207-211.
• 49 Schimke I, Müller J, Priem F. et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption.. J Am Coll Cardiol 2001; 38: 178-183.
• 50 Schuff-Werner P, Gohlke H, Bartmann U. et al. The HELP-LDL-apheresis multicentre study. An angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of Coronary heart disease.. Europ J Clin Invest 1994; 24: 724-732.
• 51 Shimoyama T, Sawada K, Hiwatashi N. et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001; 16 (01) 2-1.
• 52 Stegmayr BG, Almroth G, Berlin G. et al. Plasmaexchange or immunadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi Center study.. Int J Artif Organs 1999; 22: 81-87.
• 53 Suckfull M, Thifry J, Schorn K. et al. Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: a prospective, randomized study.. Acta Otolaryngol (Stockh.) 1999; 119: 763-766.
• 54 Suzuki Y, Yoshimura N, Saitoh Y, Saniabadi AR. Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication.. J Clin Apher 2003; 18 (01) 2-40.
• 55 Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk.. Curr Opin Lipidol 1998; 9: 521-526.
• 56 Ueki Y, Nakamura H, Kanamoto Y. et al. Comparison of lymphocyte depletion and clinical effectiveness on filtration leukocytapheresis in patients with rheumatoid arthritis.. Ther Apher 2001; 5 (06) 455-461.
• 57 Ueki Y, Yamasaki S, Kanamoto Y. et al. Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis.. Rheumatology (Oxford) 2000; 39 (02) 165-171.
• 58 Yamasaki S, Ueki Y, Nakamura H. et al. Effect of filtration leukocytapheresis therapy: modulation of white blood cell enzyme activities in patients with rheumatoid arthritis.. Artif Organs 2002; 26 (04) 378-384.
• 59 Zeigler ZR, Shadduck RK, Nath R, Andrews DF. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant associated thrombotic microangiopathy.. Bone Marrow Transplant 1996; 17: 81-82.